Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Facilities Realignment

Facilities Realignment

9 Months Ended

Sep. 30, 2013

FACILITIES REALIGNMENT

The following table presents a rollforward of the Company’s restructuring reserve from December 31, 2012 to September 30, 2013, of which approximately $1.0 million is included in other accrued expenses and $1.2 million is included in long-term liabilities as of September 30, 2013. The Company recognizes accretion expense in Other income (expense), net in the Condensed Consolidated Statement of Operations and Comprehensive Loss.



	Sales Services			Marketing Services			Discontinued Operations			Total
Balance as of December 31, 2012	$	2,027		$	637		$	615		$	3,279
Accretion	84			—			22			106
Adjustments	—			—			—			—
Payments	(841		)	(157		)	(211		)	(1,209		)
Balance as of September 30, 2013	$	1,270		$	480		$	426		$	2,176

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details